Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (111-120 of 244) with videos related to

Pageof 25
Sort By:
Blood|July 1, 2022
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCLKai Rejeski, Zhijie Wu, Viktoria Blumenberg, et al.
Annals of Hematology|October 20, 2023
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Blood|December 5, 2013
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330Christina Krupka, Peter Kufer, Roman Kischel, et al.
Haematologica|February 17, 2022
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignanciesDavid M Cordas Dos Santos, Kai Rejeski, Michael Winkelmann, et al.
Cytotherapy|April 13, 2023
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Leukemia & Lymphoma|February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomasEckhart Weidmann, Georg Hess, Kai U Chow, et al.
BMC Infectious Diseases|January 29, 2021
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case reportKai Rejeski, Wolfgang G Kunz, Martina Rudelius, et al.
Hemasphere|February 22, 2021
Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-CellsPhilipp Karschnia, Felix Strübing, Nico Teske, et al.
Blood|February 26, 2025
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemiaAndreas Linder, Daniel Nixdorf, Niklas Kuhl, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 21, 2019
Advances in cancer immunotherapy 2019 - latest trendsStephan Kruger, Matthias Ilmer, Sebastian Kobold, et al.
Pageof 25

Showing results (111-120 of 244) with videos related to

Sort By:
Pageof 25
Blood|July 1, 2022
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCLKai Rejeski, Zhijie Wu, Viktoria Blumenberg, et al.
Annals of Hematology|October 20, 2023
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Blood|December 5, 2013
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330Christina Krupka, Peter Kufer, Roman Kischel, et al.
Haematologica|February 17, 2022
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignanciesDavid M Cordas Dos Santos, Kai Rejeski, Michael Winkelmann, et al.
Cytotherapy|April 13, 2023
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Leukemia & Lymphoma|February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomasEckhart Weidmann, Georg Hess, Kai U Chow, et al.
BMC Infectious Diseases|January 29, 2021
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case reportKai Rejeski, Wolfgang G Kunz, Martina Rudelius, et al.
Hemasphere|February 22, 2021
Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-CellsPhilipp Karschnia, Felix Strübing, Nico Teske, et al.
Blood|February 26, 2025
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemiaAndreas Linder, Daniel Nixdorf, Niklas Kuhl, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 21, 2019
Advances in cancer immunotherapy 2019 - latest trendsStephan Kruger, Matthias Ilmer, Sebastian Kobold, et al.
Pageof 25